A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: A randomized, double-blinded study

Drugs under Experimental and Clinical Research

Volumn 31, Issue SUPPL. VOL 31, 2005, Pages 31-44

  Castano G ^a   Más, Rosa ^b   Fernandez L ^b   Illnait, J ^b   Mendoza, S ^b   Gamez R ^b   Fernandez J ^b   Mesa, M ^a  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; D 003; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE RELAXANT AGENT; NITRATE; ORAL ANTIDIABETIC AGENT; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLEEDING TIME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SUGARCANE;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED;

EID: 31344440243     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Murray C.J.L., López A.D. Alternate projections of mortality and disability by cause 1990-2020. Global Burden Disease Study. Lancet, 349, 1498, 1997.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA, 251, 365, 1984.
3. Frick M.H., Elo O., Happa K. et al. Helsinki Heart Study: Primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med., 317, 1237, 1987.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383, 1994.
5. Sacks F.M., Pfeffer M.A., Moyé L.A. et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001, 1996.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet, 360, 7, 2002.
7. Shepherd S., Cobbe S.M., Ford I. et al., for the West of Scotland Coronary Prevention. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 301, 1995.
8. Shepherd J., Blauw G.J., Murphy M.B. et al., on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled study. Lancet, 360, 1623, 2002.
9. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486, 2001.
10. Pyorala K., De Backer G., Graham I., on behalf of the Task Force: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 1994, 15, 1300.
11. Smith D.G., Leslie S.J., Szucs T.D., McBride S. et al. Cost of treating to a modified European Atheroesclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. Clin. Drug Invest., 17, 185, 1999.
12. Muls E., De Backer G., De Bacquer D. et al. LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals. Pharmacoepidemiol., 19, 219, 2000.
13. Lea A.P., McTavish D. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidemia. Drugs, 53, 828, 1997.
14. Davidson M.H. Rosuvastatin: A highly efficacious statin for the treatment of dyslipidemia. Expert Opin. Invest. Drugs, 11, 125, 2002.
15. Ose L., Kastelein J.J.P., Scott R. et al., for the WSEDP Research Group. Efficacy and six-month safety of simvastatin 80 mg/d: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr. Metab. Cardiov. Dis., 8, 135, 1998.
16. Baker S.K., Tarnopolsky, M.A. Statin myopathies: Patophysiologic and clinical perspectives. Clin. Invest. Med., 24, 258, 2001.
17. Mas R. Policosanol. Drugs of the Future, 25, 569, 2000.
18. Canetti M., Morera M., Illnait J., et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int. J. Clin. Pharmacol. Res., XV, 159, 1995.
19. Benítez M., Romero C., Más R. et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr. Ther. Res., 58, 859, 1997.
20. Más R., Castaño G., Illnait J. et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin. Pharmacol. Ther., 65, 439, 1998.
21. Ortensi G., Gladstein H., Valli H., Tesone P.A. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr. Ther. Res., 58, 390, 1997.
22. Castaño G., Más R., Arruzazabala M.L., et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int. J. Clin. Pharm. Res., XIX, 105, 1999.
23. Torres O., Agramonte A.J., Illnait J. et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care, 18, 393, 1995.
24. Castaño G., Menéndez R., Más R. et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated to type 2 diabetes mellitus. Int. J. Clin. Pharmacol. Res., XXII, 89, 2002.
25. Castaño G., Fernández L., Más R. et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and type 2 diabetes mellitus. Clin. Drug Invest., 23, 639, 2003.
26. Menéndez R., Fernández I., Del Río A. et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol. Res., 27, 199, 1994.
27. Menéndez R, Arruzazabala ML, Más R et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Brit. J. Nutr., 77, 923, 1996.
28. Menéndez R., Amor A., Rodeiro I. et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch. Med. Res., 32, 8, 2001.
29. Arruzazabala M.L., Más R., Molina V. et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int. J. Tissue React., XX, 119, 1998.
30. Menéndez R., Más R., Amor A.M. et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Brit. J. Clin. Pharmacol., 50, 255, 2000.
31. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs of the Future, 29, 773, 2004.
32. Menéndez R., Marrero D., Mas R. et al. In vitro and in vivo study of octacosanol metabolism. Arch. Med. Res., 36, 113, 2005.
33. Gámez R., Mendoza S., Más R. et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr. Ther. Res., 61, 8, 2000.